Current Status and Challenges of Precision Medicine in Biliary Tract Cancer

DOI

Bibliographic Information

Other Title
  • 胆道癌におけるPrecision medicineの現状と課題

Description

<p>Precision medicine in biliary tract cancer is advancing rapidly with recent advances incomprehensive genomic panel (CGP). In the severe prognosis of biliary tract cancer, precision medicine is an important therapeutic strategy in addition to conventional cytotoxic anticancer drugs and immune checkpoint inhibitors. In particular, the types and rates of cancer gene aberrations vary by subpopulation, such as intrahepatic cholangiocarcinoma and gallbladder cancer, and there are many target molecules such as FGFR2 fusion gene and HER2 gene amplification that can lead to treatment. It is important to link the CGP to precision medicine in biliary tract cancer, including what to use and when to perform the test.</p>

Journal

  • Tando

    Tando 38 (1), 70-75, 2024-03-31

    Japan Biliary Association

Keywords

Details 詳細情報について

  • CRID
    1390862623771328256
  • DOI
    10.11210/tando.38.70
  • ISSN
    18836879
    09140077
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top